Familial Cancer

, Volume 15, Issue 4, pp 677–687 | Cite as

Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families

  • Janice P. Dutcher
  • Peter H. Wiernik
  • Leticia Varella
  • Rangaswamy Chintapatla
Original Article


The relationship between renal cell cancer (RCC) and hematologic malignancy (HM) in the same individual has been reported for more than 20 years, and is noted in SEER database studies. Family histories suggest a familial association as well. This study evaluates the occurrence of renal cell cancer and hematologic malignancies in individual patients and families, and the occurrence of age-of-onset anticipation among generations. Family history data from our familial patient registry, including more than 700 pedigrees of familial hematologic malignancies, and 700 patients with renal cell cancer, were reviewed. Twenty-six patients with a personal history of both RCC and HM are reported. Seventy four patients with RCC are noted to have 95 family members with HM. Consistent with past reports, there was male predominance among the patients with both diseases (71 %), and among the RCC patients’ relatives with HM (57 %). Also consistent was a predominance of lymphoid malignancies in those with both diseases (92 %) and in the HMs among family members of RCC patients (79 %). The majority (95 %) of HM relatives were first or second degree relatives of the patient with RCC. Thirty of 34 parent/child pairs demonstrated age of onset anticipation in which the child developed either disease at a younger age than the parent. The co-occurrence of RCC and HM in the same patient has been shown to be significantly greater than expected. Families also appear to have an increased association. The appearance of anticipation suggests that genetic factors may be significant in this association of RCC and HM.


Renal cell cancer Familial hematologic malignancies Lymphoma 



Supported in part by Cancer Research Foundation of New York, Chappaqua NY; Children’s Leukemia Research Association, Garden City, New York; Long Island League Against Cancer (L.I.L.A.C.), New York; Jewish Community Trust, New York.

Authors contribution

All authors have contributed to this manuscript, by collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of the manuscript. In addition, Drs Wiernik and Dutcher have provided study conception and design and have contributed subjects for the study.

Compliance with ethical standards

Conflict of interest

Drs. Varella and Chintapatla have no conflicts to disclose. Dr. Wiernik participates in speakers bureau and advisory boards for Novartis and Celgene. Dr. Dutcher participates in speakers bureau and advisory boards for Prometheus, Novartis and Pfizer, and is a member of data safety and monitoring boards for Bristol-Myers-Squibb, Tracon, and PrECOG.

Informed consent

The study protocol was approved by the institutional review board. All participants gave informed consent. All procedures performed were in accordance with ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr (1991) Second cancers following non-Hodgkin’s lymphoma. Cancer 67:2002–2009CrossRefPubMedGoogle Scholar
  2. 2.
    Travis LB, Curtis RE, Glimelius B, Holowat YE, van Leeuwen FE, Lynch CF, Adami J, Gospodarowicz M, Wacholder S, Inskip P (1993) Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst 85:1932–1937CrossRefPubMedGoogle Scholar
  3. 3.
    Ohsawa M, Hashimoto M, Yasunaga Y, Shingu N, Aozasa K (1998) Characteristics of non-Hodgkin’s lymphoma complicated by renal cell malignancies. Oncology 55:482–486CrossRefPubMedGoogle Scholar
  4. 4.
    Anderson CM, Puszatai L, Palmer JL, Cabanillas F, Ellerhorst JA (1998) Coincidental renal cell carcinoma and non-Hodgkin’s lymphoma: the M.D. Anderson experience and review of literature. J Urol 159:714–716CrossRefPubMedGoogle Scholar
  5. 5.
    Tihan T, Filippa D (1996) Coexistence of renal cell carcinoma and malignant lymphoma: a causal relationship or coincidental occurrence. Cancer 77:2325–2339CrossRefPubMedGoogle Scholar
  6. 6.
    Kunther A, Wiernik PH, Dutcher JP (2006) Renal parenchymal tumors and lymphoma in the same patient: case series and review of the literature. Am J Hematol 81:271–280CrossRefGoogle Scholar
  7. 7.
    Dutcher JP, Wiernik PH (2011) Renal cell carcinoma and hematologic malignancy in the same patients. J Invest Med 59:634 (abst)Google Scholar
  8. 8.
    Dutcher JP, Wiernik PH (2015) Renal cell carcinoma (RCC) in patients with a personal or family history of hematologic malignancies (HM). Clin Adv Hematol Oncol 13:257–260PubMedGoogle Scholar
  9. 9.
    Nishikubo C, Kunkel LA, Figlin R, Belldegrun A, Rosen P, Elashoff R, Wang H, Territo MC (1996) An association between renal cell carcinoma and lymphoid malignancies: a case series of eight patients. Cancer 78:2421–2427CrossRefPubMedGoogle Scholar
  10. 10.
    Kurtz JE, Andres E, Maloisel F, Herbrecht R, Dufour P (1999) Renal cell carcinoma and type B lymphomatous proliferation: a fortuitous association? Rev Med Intern 20:329–332CrossRefGoogle Scholar
  11. 11.
    Bernie JE, Albers L, Baird S, Parsons CL (2000) Synchronous ipsilateral renal adenocarcinoma, transitional cell carcinoma of the renal pelvis and metastatic renal lymphoma. J Urol 164:773–774CrossRefPubMedGoogle Scholar
  12. 12.
    Shah SA, Ormerod AD, Husain A, Kohle P, Culligan D (1999) Primary cutaneous CD30 (Ki-1) positive anaplastic large cell lymphoma associated with renal cell carcinoma. Br J Dermatol 140:971–972CrossRefPubMedGoogle Scholar
  13. 13.
    Shah IA, Haddad FS, Gani OS, Alfsen CC (1997) An association between renal cell carcinoma and lymphoid malignancies: a case series of eight patients. Correspondence. Cancer 80:1005–1006CrossRefPubMedGoogle Scholar
  14. 14.
    Wang BY, Strauchen JA, Rabinowiz D (2001) Renal cell carcinoma with intravascular lymphomatosis. A case report of unusual collision tumours with review of literature. Arch Pathol Lab Med 125:1239–1241PubMedGoogle Scholar
  15. 15.
    Yagisawa K, Ohno Y, Toba K, Tsuchiyama J, Suzuki N, Nikkuni K, Aoki S, Aizawa Y (2001) Three cases of malignant lymphoma accompanied by renal cell carcinoma. Rinsho Ketsueki 42:616–620PubMedGoogle Scholar
  16. 16.
    Barista I (1997) An association between renal cell carcinoma and lymphoid malignancies. Cancer 80:1004–1005CrossRefPubMedGoogle Scholar
  17. 17.
    Hanawa Y, Tanomogi H, Hasegawa S (1999) Renal cell carcinoma in a patient with malignant lymphoma: a case report. Hinyokika Kiyo 45:843–845PubMedGoogle Scholar
  18. 18.
    Marquez-Moreno AJ, Manas-Uxo J, Amores-Ramirez F, Aquilar Cuevas R, Ortega Jiménez MV, Leiva Vera C, Pérez Rodriguez D (2003) Synchronous chromophobe renal carcinoma and centrocytic lymphoma. Arch Esp Urol 56:415–417PubMedGoogle Scholar
  19. 19.
    Takagi Y, Senda M, Tanaka J (2000) Renal cell carcinoma in a patient with malignant lymphoma: a case report. Hinyokika Kiyo 46(8):545–547PubMedGoogle Scholar
  20. 20.
    Fernandez-Pello S, Rodrigues-Villamil L, Gonzalez-Rodriguez I, Venta V, Cuervo J, Menéndez CL (2013) Lymph node non-Hodgkin’s lymphoma incidentally discovered during a nephrectomy for renal cell carcinoma. World J Clin Cases 1:121–123CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bhandari MS, Mazumder A, Jagannath S, Vesole DA (2008) Association between renal cell carcinoma and plasma cell dyscrasias: a case series of six patients. Clin Lymphoma Myeloma 8:188–190CrossRefPubMedGoogle Scholar
  22. 22.
    Aljitawi OS, Allen M, Zhang D, Dasouki M, Abhyankar S, Ganguly S, McGuirk JP, VanVeldhuizen P (2012) Coexistent non-Hodgkin’s lymphoma and renal cell carcinoma in a patient with von Hippel–Lindau disease: a case report. J Blood Lymph. doi: 10.4172/2165-7831.1000101 Google Scholar
  23. 23.
    Hwang SM, Kuyava JM, Grande JP, Swetz KM (2015) Metastatic renal cell carcinoma mimicking diverticulitis in a patient with chronic lymphocytic leukaemia. BMJ Case Rep bcr2014206161Google Scholar
  24. 24.
    Sargin G, Yavasoglu I (2013) Renal cell carcinoma and chronic lymphocytic leukemia. Med Oncol 30:547–548CrossRefPubMedGoogle Scholar
  25. 25.
    Solovan C, Smiszek R, Wickenhauser C, Chitikariu E (2013) Postoperative pyoderma gangrenous in association with renal cell carcinoma and chronic lymphocytic leukemia. Infect Dis Ther 2:75–80CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Deeb R, Zhang Z, Ghanem T (2012) Metastatic renal cell carcinoma to the parotid gland in the setting of chronic lymphocytic leukemia [published online February 19]. Case Rep Med. doi: 10.1155/2012/265708 PubMedPubMedCentralGoogle Scholar
  27. 27.
    Serefhanoglu S, Buyukasik Y, Goker H, Akin SC, Akin S, Sayinalp N, Haznedaroglu IC, Ozcebeo L (2010) Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature. Med Oncol 27:55–58CrossRefPubMedGoogle Scholar
  28. 28.
    Thway K, Freeman A, Woodhouse CR, Fisher C (2008) Epithelial–stromal tumor of seminal vesicle in a patient with chromophobe renal cell carcinoma and small lymphocytic lymphoma. Ann Diagn Pathol 12:433–499CrossRefPubMedGoogle Scholar
  29. 29.
    Schafernak KT, Yang XJ, Hsueh W, Leestma JZ, Stagl J, Goldman S (2007) Pediatric renal cell carcinoma as second malignancy: reports of two cases and a review of the literature. Can J Urol 14:3739–3744PubMedGoogle Scholar
  30. 30.
    Sakai A, Kawano M, Kuramoto A (1991) Interleukin-6 produced by renal cell carcinoma cells and progression of multiple myeloma. N Engl J Med 324:1893–1894CrossRefPubMedGoogle Scholar
  31. 31.
    Prosvic P, Dulicek P, Odrazka K, Navratilová J, Morávek P, Veselský Z (2003) Asynchronous occurrence of three neoplastic diseases: chronic B-cell lymphatic leukemia, renal carcinoma and prostatic carcinoma. Rozhi Chir 82:583–586Google Scholar
  32. 32.
    Licci S, Brenna A, Abbate I, Ascani S (2008) The association between non-Hodgkin lymphoma and renal cell carcinoma in an HIV-positive patient: clinico-pathological features and pathogenic implications. Am J Hematol 83:759CrossRefPubMedGoogle Scholar
  33. 33.
    Dincol D, Arican A, Ensari A, Akyar S, Bedűk Y, Cenqiz A (1999) Concurrent occurrence of three neoplasms including non-Hodgkin’s lymphoma, renal cell carcinoma and leiomyoma in the same kidney. Med Oncol 16:134–138CrossRefPubMedGoogle Scholar
  34. 34.
    Uehara E, Tasaka T, Matsuashi Y, Suemitsu I, Tamura T, Kuwajima M, Nagai M (2001) Adrenal gland lymphoma accompanied by renal cell carcinoma. Rinsho Ketsueki 42:710–712PubMedGoogle Scholar
  35. 35.
    Lolli E, Matteoni R, Barbieri A, D’Ambrosi M, Archontakis F (1998) Non-Hodgkin’s lymphoma, renal carcinoma, and meningioma. Ann Ital Chir 69:101–104PubMedGoogle Scholar
  36. 36.
    Mohren M, Essbach U, Franke A, Klink A, Maas C, Markmann I, Pelza F, Jentsch-Ullrich K (2003) Acute myelofibrosis in a patient with diffuse large cell non-Hodgkin’s lymphoma and renal cancer. Leuk Lymphoma 44:1603–1607CrossRefPubMedGoogle Scholar
  37. 37.
    Ceres F, Rivera F, Yague JL, Blanco J, Garcia-Rijo M, Sánchez de la Nieta MD, Alcázar R, de la Torre M (2003) Non-Hodgkin’s lymphoma, IgA nephropathy and renal cell carcinoma. Nefrologia 23:554–557PubMedGoogle Scholar
  38. 38.
    Guo R, Chang L, Liu Z, Li AX, Huang Q, Ann DK, Wang HC, Lin CW, Wu X, Yuan YC, Yen Y (2011) Canonical NF-κB pathway links tumorigenesis of synchronous mantle-cell lymphoma, clear cell renal cell carcinoma, and gastrointestinal stromal tumor. J Clin Oncol 29:e257–e261CrossRefPubMedGoogle Scholar
  39. 39.
    Choueiri TK, Baz RC, McFadden CM, Khasawne KM, Karam MA, Kelly M, Hussein MA (2008) An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU Int 101:712–715CrossRefPubMedGoogle Scholar
  40. 40.
    Wu WW, Chu JT, Nael A, Rezk SA, Romansky SG, Shane L (2014) Thyroid-like follicular carcinoma of the kidney in a young patient with history of pediatric acute lymphoblastic leukemia. Case Rep Pathol 2014:313974PubMedPubMedCentralGoogle Scholar
  41. 41.
    Czarnecka AM, Oborska S, Rzepecki P, Szczylik C (2014) Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. Future Oncol 11:17–26CrossRefGoogle Scholar
  42. 42.
    Labno-Kirszniok K, Nieszporek T, Wiecek A, Helbig G, Lubinski J (2013) Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel–Lindau disease. Hered Cancer Clin Pract 11:11CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Varoglu E, Kaya B, Sari O (2013) Chronic myeloid leukemia detected on FDG PET/CT imaging in a patient with renal cell carcinoma. Rev Esp Med Nucl Imagen Mol 32:43–45PubMedGoogle Scholar
  44. 44.
    Scott M, Lawrance J, Dennis M (2012) Regression of a renal cell carcinoma following allogeneic peripheral blood stem cell transplant for acute myeloid leukaemia: evidence of a graft-versus-tumour effect without significant graft-versus-host disease. Br J Haematol 159:1CrossRefPubMedGoogle Scholar
  45. 45.
    Al-Najjar F, Jarkowski A 3rd (2011) Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukema—easier said than done? A case report. J Oncol Pharm Pract 17:436–439CrossRefPubMedGoogle Scholar
  46. 46.
    Pal SK, Gupta RK, Dosik G, Figlin RA (2009) Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach. Curr Oncol 16:44–47CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Parajuli R, Altman J, Kuzel T, Perdekamp M, Tallman M (2010) Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association? Am J Hematol 85:829CrossRefPubMedGoogle Scholar
  48. 48.
    Huang FS, Zwerdling T, Stern LE, Ballard ET, Warner BW (2011) Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia. J Pediatr Hematol Oncol 23:609–611CrossRefGoogle Scholar
  49. 49.
    Varella L, Chintapatla R, Wiernik PH, Dutcher JP (2012) Association of renal cell carcinoma and hematologic malignancies. Br J Urol 110(Suppl 2):10–11 (abst)Google Scholar
  50. 50.
    Chintapatla R, Varella L, Wiernik P, Rusciano V, Dutcher JP (2012) Association of renal cell carcinoma and B-cell hematologic malignancy. Blood 120(Suppl) (epub) (Abst 5086)Google Scholar
  51. 51.
    Varella L, Chintapatla R, Wiernik PH, Rusciano V, Dutcher JP (2013) Association of renal cell and hematologic malignancies. J Clin Oncol 31(suppl):204 (abst 449)Google Scholar
  52. 52.
    Alexandrescu DT, Wiernik PH (2007) The influence of parental age and gender on anticipation in familial B-cell malignancies. Med Oncol 24:55–67CrossRefPubMedGoogle Scholar
  53. 53.
    NCI SEER Stat Facts 2010–2012.
  54. 54.
    Horwitz M, Wiernik PH (1999) Pseudoautosomal linkage of Hodgkin disease. Am J Hum Genet 65:1413–1422CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Wiernik PH, Wang SQ, Hu XP, Marino P, Paietta E (2000) Age of onset evidence for anticipation in familial non-Hodgkin’s lymphoma. Br J Haematol 108:72–79CrossRefPubMedGoogle Scholar
  56. 56.
    Singer EA, Bratslavsky G, Middelton L, Srinivasan R, Linehan WM (2011) Impact of genetics on diagnosis and treatment of renal cancer. Curr Urol Rep 12:47–55CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JW, Collins D, Majoor-Krakauer D (1988) Von Hippel Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332:268–269CrossRefPubMedGoogle Scholar
  58. 58.
    Seizinger BR, Smith DI, Filling-Katz MR, Neumann H, Green JS, Choyke PL, Anderson KM, Freiman RN, Klauck SM, Whaley J (1991) Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease. Proc Natl Acad Sci USA 88:2864–2868CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Whaley JM, Naglich J, Gelbert L, Lamiell JM, Green JS, Collins D, Neumann HP, Laidlaw J, Li FP (1994) Germ-line mutations in the von Hippel–Lindau tumor suppressor gene are similar to somatic von Hippel–Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55:1092–1102PubMedPubMedCentralGoogle Scholar
  60. 60.
    Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM (1996) Molecular cloning of the von Hippel–Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1242:201–210PubMedGoogle Scholar
  61. 61.
    Toujani S, Dessen P, Ithzar N, Danglot G, Richon C, Vassetzky Y, Robert T, Lazar V, Bosq J, De Costa L, Pérot C, Ribraq V, Patte C, Wiels J, Bernheim A (2009) High resolution genome-wide analysis of chromosomal alterations in Burkitt’s lymphoma. PLoS ONE 4:e7089CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Farley N, Schmidt LS, Mester JL, Peña-Llopis S, Pavia-Jimemez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middleton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie J, Dahia PL, Eng C, Linehan WM, Brugarolas J (2013) A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11(9):1061–1071CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Brugarolas J (2014) Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 32:1968–1976CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Wang SS, Gu YF, Wolff N, Stefanius K, Christie A, Day A, Hammer RE, Xie XJ, Rakheja D, Pedrosa L, Carroll T, McKay RM, Kapur P, Brugarolas J (2014) Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci USA 111:16538–16543CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Schmidt LS, Junker K, Weirich G, Glenn G, Choyke P, Lubensky L, Zhuang Z, Jeffers M, Vande Woude G, Neumann H, Walther M, Linehan WM, Zbar B (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58:1719–1722PubMedGoogle Scholar
  66. 66.
    Schmidt LS, Junker K, Nakagawa N, Kinjerski T, Weirich G, Miller M, Lubensky L, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richards S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B (1999) Novel mutations in the MET protooncogene in papillary renal carcinomas. Oncogene 18:2343–2350CrossRefPubMedGoogle Scholar
  67. 67.
    Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98:3387–3392CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner M, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman M, Linehan WM, Zbar B, Schmidt LS (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with Birt–Hogg–Dube syndrome. Cancer Cell 2:157–164CrossRefPubMedGoogle Scholar
  69. 69.
    Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metivalli AR, Srinivasan R, Linehan WM (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32:431–437CrossRefPubMedGoogle Scholar
  70. 70.
    Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA, Meriono MJ, Walther MM, Zbar B, Linehan WM (2005) High frequency of somatic frameshift BHD gene mutations in Birt–Hogg–Dube-associated renal tumors. JNCI 97:931–935CrossRefPubMedGoogle Scholar
  71. 71.
    Mester JL, Moore RA, Eng C (2013) PTEN germline mutations in patients initially tested for other hereditary cancer syndromes; would use of risk assessment tools reduce genetic testing? Oncologist 18:1083–1090CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Shuch B, Ricketts CJ, Vocke CD, Komiya T, Middleton LA, Kaufman EC, Merino MJ, Metwalli AR, Dennis P, Linehan WM (2013) Germline PTEN mutation Cowden syndrome: an under-appreciated form of hereditary kidney cancer. J Urol 190:1990–1998CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Musilova K, Mraz M (2015) MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia 29:1004–1017CrossRefPubMedGoogle Scholar
  74. 74.
    Papadavid E, Korkolopoulou P, Levidou G, Saetta AA, Papadaki T, Siakantaris M, Nikolaou V, Okonomidi A, Chatziandreou I, Marinos L, Kollalexi A, Stratigos A, Rigopoulos D, Psyrri A, Patsouris E, Antoniou C (2014) In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features. Exp Dermatol 12:931–933CrossRefGoogle Scholar
  75. 75.
    Cristofoletti C, Picchio MC, Lazzeri C, Tocco V, Pagani E, Bresin A, Mancini B, Pasarelli F, Facchiano A, Scala E, Lombardo GA, Cantonetti M, Caprini E, Russo G, Narducci MG (2013) Comprehensive analysis of PTEN status in Sezary syndrome. Blood 122:3511–3520CrossRefPubMedGoogle Scholar
  76. 76.
    Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollbert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, Dörken B, Janz M, Dimhofer S, Lenz P, Hummel M, Tzankov A, Lenz O (2013) PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 110:12420–12425CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon, or the combination of interferon plus temsirolimus for patients with advanced renal cell carcinoma and poor risk features. N Engl J Med 356:2271–2281CrossRefPubMedGoogle Scholar
  78. 78.
    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomized, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMedGoogle Scholar
  79. 79.
    Wiernik PH, Ashwin M, Hu XP, Paietta E, Brown K (2001) Anticipation in familial chronic lymphocytic leukemia. Br J Haematol 113:407–411CrossRefPubMedGoogle Scholar
  80. 80.
    Deshpande HA, Hu XP, Marino P, Jan NA, Wiernik PH (1998) Anticipation in plasma cell dyscrasias. Br J Haematol 103:696–703CrossRefPubMedGoogle Scholar
  81. 81.
    Lynch HT, Watson P, Tarantolo S, Wiernik PH, Quinn-Laquer B, Bergsagel I, Huiart L, Olopade OI, Sobol H, Sanger W, Hogg D, Weisenburger D (2005) Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23:685–693CrossRefPubMedGoogle Scholar
  82. 82.
    Wiernik PH, Wickramasinghe D, Dutcher JP (2015) Families with both Hodgkin’s lymphoma and myeloma in their pedigrees. Clin Adv Hematol Oncol 13:257–260PubMedGoogle Scholar
  83. 83.
    Wiernik PH, Hu X, Ratech H, Fineberg S, Marino P, Schleider MA, Etkind P, Walewski JA (2000) Non-Hodgkin’s lymphoma in women with breast cancer. Cancer J 6:336–342PubMedGoogle Scholar
  84. 84.
    Etkind P, Du J, Khan A, Pillitteri J, Wiernik PH (2000) Mouse mammary tumor virus-like ENV gene sequences in human breast tumors and in a lymphoma of a breast cancer patient. Clin Cancer Res 6:1273–1278PubMedGoogle Scholar
  85. 85.
    Etkind PR, Stewart AFR, Dorai T, Purcell DJ, Wiernik PH (2004) Clonal isolation of different strains of mouse mammary tumor virus-like DNA sequences from both breast tumors and non-Hodgkin’s lymphomas of individual patients diagnosed with both malignancies. Clin Cancer Res 10:5656–5664CrossRefPubMedGoogle Scholar
  86. 86.
    Kinch A, Cavelier L, Bengtsson M, Baechlund E, Enblad G, Backlin C, Thunberg U, Sundström C, Pauksens K (2014) Donor or recipient origin of post-transplant lympho-proliferative disorders following solid organ transplantation. Am J Transplant 14:2838–2845CrossRefPubMedGoogle Scholar
  87. 87.
    Gratama JW, Zea AH, Bolhuis RL, Ochoa AC (1999) Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy. Cancer Immunol Immunother 48:263–269CrossRefPubMedGoogle Scholar
  88. 88.
    Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, Miwa H, Lim KJ, Das KM (2014) Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol 20:5461–5473CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Pereira MI, Medeiros JA (2014) Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas. World J Gastroenterol 20:684–698CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Sakai T, Ogura Y, Narita J, Suto T, Kimura D, Ainais S, Fujita H, Kamida M (2003) Simultaneous early adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach associated with Helicobacter pylori infection. Gastric Cancer 6:191–196CrossRefPubMedGoogle Scholar
  91. 91.
    Neri A, Barriga F, Inghirami G, Knowles DM, Neeguave J, Magrath IT, Dalla-Favera R (1991) Epstein–Barr virus infection precedes clonal expansion in Burkitt’s and acquired immunodeficiency syndrome-associated lymphoma. Blood 77:1092–1095PubMedGoogle Scholar
  92. 92.
    Polz-Gruszka D, Stec A, Dworzanski J, Potz-Dacewicz M (2015) EVB, HSV, CMV and HPV in laryngeal and oropharyngeal carcinoma in Polish patients. Anticancer Res 35:1657–1661PubMedGoogle Scholar
  93. 93.
    Jiang R, Ekshyyan O, Moore-Medlin T, Rong X, Nathan S, Gu X, Abreo F, Rosenthal EL, Shi M, Gudry JT, Scott RS, Hutt-Fletcher LM, Nathan CA (2015) Association between human papilloma virus/Epstein–Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med 44:28–36CrossRefPubMedGoogle Scholar
  94. 94.
    Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T (2009) Definition, prognostic factors, treatment and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus. J Clin Oncol 27:453–459CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Yoshida N, Chihara D (2015) Incidence of adult T-cell leukemia/lymphoma in nonendemic areas. Curr Treat Options Oncol 16:7. doi: 10.1007/s11864-014-0321-0325 CrossRefPubMedGoogle Scholar
  96. 96.
    Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S (2002) Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect Dis 2:344–352CrossRefPubMedGoogle Scholar
  97. 97.
    Pogo BG, Melana SM, Moran H, Holland JF (2001) Presence of MMTV-like env gene sequences in human breast cancer. Breast Cancer Res Treat 125:295–297CrossRefGoogle Scholar
  98. 98.
    Melana SM, Nepomnaschy I, Hasa J, Djougarian A, Holland JF, Pogo BG (2010) Detection of human mammary tumor virus proteins in human breast cancer cells. J Virol Methods 163:157–161CrossRefPubMedGoogle Scholar
  99. 99.
    Stratton KL, Schrader KA, Manschreck C, Rau-Murthy R, Corines M, Dutcher J, Wiernik P, Palomba L, Portlock C, Murali R, Klein RJ, Coleman J, Stadler Z, Offit K, Vijai J (2013) Renal cell carcinoma and non-Hodgkin’s lymphoma: genomic approaches to identification of shared susceptibility. Proc Soc Urol Oncol (abst)Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Janice P. Dutcher
    • 1
    • 2
  • Peter H. Wiernik
    • 1
    • 2
  • Leticia Varella
    • 2
    • 3
  • Rangaswamy Chintapatla
    • 2
    • 4
  1. 1.Our Lady of Mercy Cancer CenterNew York Medical CollegeBronxUSA
  2. 2.Cancer Research Foundation of New YorkChappaquaUSA
  3. 3.Cleveland ClinicClevelandUSA
  4. 4.Kadlec Regional Medical CenterRichlandUSA

Personalised recommendations